![Shuang Li](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shuang Li
Directeur/Bestuurslid bij YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.
Vermogen: 84 531 $ op 31-05-2024
Profiel
Shuang Li is currently working as an Executive Director & Deputy General Manager at YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
since 2018.
Additionally, Mr. Li is also working as a Director at HEC Pharm Co., Ltd.
Mr. Li completed their undergraduate degree from China Three Gorges University in 2004.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
30-06-2023 | 66 800 ( 0.01% ) | 84 531 $ | 31-05-2024 |
Actieve functies van Shuang Li
Bedrijven | Functie | Begin |
---|---|---|
YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Directeur/Bestuurslid | 08-06-2018 |
HEC Pharm Co., Ltd.
![]() HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Directeur/Bestuurslid | - |
Opleiding van Shuang Li
China Three Gorges University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
HEC Pharm Co., Ltd.
![]() HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Health Technology |